Liver Transplant for Patients with Hepato ­cellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research

Sorafenib: Experience and Better Manage ­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
Conclusion: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2019;8:140 –140 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2019;8:141 –141 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

Apple 2019
Liver Cancer 2019;8:142 –142 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma
Liver Cancer 2019;8:1 –5 (Source: Liver Cancer)
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Systemic Treatment for Advanced Hepatocellular Carcinoma
Background: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line sorafenib has been the standard of care for a decade, but the treatment landscape is expanding. This review provides a practical overview of current and future systemic treatment options for advanced HCC and their place in clinical practice.Summary: First-line sorafenib and lenvatinib have shown to improve the survival of patients with advanced HCC. In the second line, regorafenib provides benefit for patients who previously tolerated sorafenib. Anti-PD1 antibodies, nivolumab and pembrolizumab, recently became available for ...
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
Conclusion: Tumor marker score had a useful predictive prognostic value in BCLC-B HCC treated with TACE. Especially in patients with a tumor marker score of 2 or greater, a poor therapeutic response should be expected, and appropriate judgement of TACE-refractory status is necessary.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 18, 2019 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2019;8:69 –69 (Source: Liver Cancer)
Source: Liver Cancer - January 31, 2019 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2019;8:70 –70 (Source: Liver Cancer)
Source: Liver Cancer - January 31, 2019 Category: Cancer & Oncology Source Type: research

Apple 2019
Liver Cancer 2019;8:71 –71 (Source: Liver Cancer)
Source: Liver Cancer - January 31, 2019 Category: Cancer & Oncology Source Type: research

Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions
Image-guided locoregional therapies (LRTs) have long been a vital part of treatment regimens for hepatocellular carcinoma (HCC). Ablation, chemoembolization, and radioembolization are examples of commonly used treatment techniques for HCC. This review describes the various methods utilized to treat HCC in the field of interventional oncology and also focuses on new and novel treatment concepts being developed in the field including the use of novel immunotherapy agents and combination therapy of LRTs with immunotherapy.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - January 16, 2019 Category: Cancer & Oncology Source Type: research

Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma
Liver Cancer 2019;8:1 –11 (Source: Liver Cancer)
Source: Liver Cancer - January 15, 2019 Category: Cancer & Oncology Source Type: research

Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
Background: Because of the rapid progression of antiviral treatment options and the increasing frequency of nonviral-related hepatocellular carcinoma (HCC) due to the aging of society, the number of HCC patients with good hepatic function has been increasing and a more detailed method of assessment of hepatic function is needed. The Child-Pugh classification (CP) is used worldwide as an assessment tool for hepatic reserve function, even though it has some weaknesses. Recently, the albumin-bilirubin (ALBI) grade, calculated based on only albumin and total bilirubin, was proposed, and recent investigations have suggested tha...
Source: Liver Cancer - November 29, 2018 Category: Cancer & Oncology Source Type: research